CA2362757A1 - Effervescent pharmaceutical formulation containing metamizole - Google Patents
Effervescent pharmaceutical formulation containing metamizole Download PDFInfo
- Publication number
- CA2362757A1 CA2362757A1 CA002362757A CA2362757A CA2362757A1 CA 2362757 A1 CA2362757 A1 CA 2362757A1 CA 002362757 A CA002362757 A CA 002362757A CA 2362757 A CA2362757 A CA 2362757A CA 2362757 A1 CA2362757 A1 CA 2362757A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- effervescent formulation
- effervescent
- metamizole
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a stable pharmaceutical effervescent formulation wi th metamizol and/or its pharmaceutically acceptable salts as active ingredients , wherein the pH of the corresponding solution is acidic.
Claims (15)
1. ~A pharmaceutical composition in the form of an effervescent formulation, characterized by metamizole and/or its pharmaceutically acceptable salts as active ingredients.
2. ~A pharmaceutical composition in the form of an effervescent formulation as claimed in claim 1, characterized by alkali metal salts and/or ammonium salts of metamizole as active ingredients.
3. ~A pharmaceutical composition in the form of an effervescent formulation as claimed in claim 1 or 2, characterized by metamizole sodium monohydrate as active ingredient.
4. ~A pharmaceutical composition in the form of an effervescent formulation as claimed in any of the preceding claims, characterized by a content of 200-1 000 mg, in particular 400-600 mg, of metamizole and/or its pharmaceutically acceptable salts per dosage unit.
5. ~A pharmaceutical composition in the form of an effervescent formulation as claimed in claim 4, characterized by a content of 500 mg of metamizole sodium monohydrate per dosage unit.
6. ~A pharmaceutical composition in the form of an effervescent formulation as claimed in any of the preceding claims, characterized by an effervescent mixture of at least one physiologically tolerated acid or its sodium salt and of a physiologically tolerated carbonate and/or bicarbonate in ratios of amounts such that the resulting solution has a pH
of from 3 to 6.5, in particular of from 4 to 6, preferably of from 4.5 to 5.
of from 3 to 6.5, in particular of from 4 to 6, preferably of from 4.5 to 5.
7. A pharmaceutical composition in the form of an effervescent formulation as claimed in claim 6, characterized by citric acid or its monosodium salt is combination with sodium carbonate and sodium bicarbonate as effervescent mixture.
8. ~A pharmaceutical composition in the form of an effervescent formulation as claimed in any of the preceding claims, characterized in that the ratio by weight of the acid(s) to the carbonate and/or bicarbonate in the effervescent mixture is between 0.7 and 2.4, in particular between 1.1 and 2.2.
9.~A pharmaceutical composition in the form of an effervescent formulation as claimed in any of the preceding claims. characterised by an optional content of a sweetener.
l0. ~A pharmaceutical composition in the form of an effervescent formulation as claimed an any of the preceding claims, characterised by an optional content of a flavor.
11. ~A pharmaceutical composition in the form of an effervescent formulation as claimed in any of the preceding claims in the form of powder, tablets or granules, which can be packed in sachets, in particular in the form of tablets.
l2. ~A pharmaceutical composition in the form of an effervescent formulation, characterized by metamizole sodium monohydrate, sodium carbonate/sodium bicarbonate, tableting excipients, where appropriate flavorings and/or sweeteners, the resulting solution having a pH of 3-6.5, in particular of 4.5-5.
13. ~A pharmaceutical composition as claimed in claim 1-12, characterized in that the effervescent formulation is stable.
14. A pharmaceutical composition as claimed in claim 1-12, characterized in that the solution of the effervescent formulation is stable and clear for at least one hour.
15. A pharmaceutical composition as claimed in claim 13 or 14, characterized in that the effervescent formulation comprises no additional stabilizing substances.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19905581.5 | 1999-02-11 | ||
| DE19905581 | 1999-02-11 | ||
| PCT/EP2000/001096 WO2000047189A1 (en) | 1999-02-11 | 2000-02-10 | Pharmaceutical effervescent formulation containing metamizol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2362757A1 true CA2362757A1 (en) | 2000-08-17 |
| CA2362757C CA2362757C (en) | 2010-08-24 |
Family
ID=7897089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2362757A Expired - Fee Related CA2362757C (en) | 1999-02-11 | 2000-02-10 | Effervescent pharmaceutical formulation containing metamizole |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1150660B1 (en) |
| JP (1) | JP2002536401A (en) |
| AT (1) | ATE258046T1 (en) |
| AU (1) | AU777234B2 (en) |
| BR (1) | BR0008442B1 (en) |
| CA (1) | CA2362757C (en) |
| DE (1) | DE50005076D1 (en) |
| ES (1) | ES2215025T3 (en) |
| HU (1) | HUP0200336A3 (en) |
| PL (1) | PL201844B1 (en) |
| PT (1) | PT1150660E (en) |
| TR (1) | TR200102279T2 (en) |
| WO (1) | WO2000047189A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103610656A (en) * | 2013-12-05 | 2014-03-05 | 昆明振华制药厂有限公司 | Preparation method of analgin tablet |
| CN104434862A (en) * | 2014-11-06 | 2015-03-25 | 石家庄正大鸿福牧业有限公司 | Veterinary metamizole sodium effervescent tablets and preparation method thereof |
| US20160317662A1 (en) * | 2013-12-16 | 2016-11-03 | Hypermarcas S.A. | Stable oral pharmaceutical composition |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BG112443A (en) | 2017-01-19 | 2018-07-31 | Adifarm Ead | Effervescent composition containing metamizole sodium monohydrate and preparation method |
| EP3928766A1 (en) | 2020-06-26 | 2021-12-29 | Usso Barnas | Pharmaceutical composition and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD41306A (en) * | ||||
| JPS52156915A (en) * | 1976-06-19 | 1977-12-27 | Hokuriku Pharmaceutical | Production of stable injection without blood solubulizing property |
| IT1265342B1 (en) * | 1993-07-19 | 1996-11-22 | Iscofar S A S Di Paolo Ghirard | PHARMACEUTICAL COMPOSITIONS BASED ON GLYCINE DERIVATIVES |
| DE59712694D1 (en) * | 1997-04-18 | 2006-08-24 | Fritz Stanislaus | STABILIZED MEDICAMENT CONTAINING CYSTEINYL DERIVATIVES |
| DE19822036A1 (en) * | 1998-05-15 | 1999-11-18 | Bayer Ag | Effervescent pharmaceutical composition with improved stability |
-
2000
- 2000-02-10 EP EP00906318A patent/EP1150660B1/en not_active Expired - Lifetime
- 2000-02-10 DE DE50005076T patent/DE50005076D1/en not_active Expired - Lifetime
- 2000-02-10 TR TR2001/02279T patent/TR200102279T2/en unknown
- 2000-02-10 CA CA2362757A patent/CA2362757C/en not_active Expired - Fee Related
- 2000-02-10 PT PT00906318T patent/PT1150660E/en unknown
- 2000-02-10 WO PCT/EP2000/001096 patent/WO2000047189A1/en active IP Right Grant
- 2000-02-10 AU AU28040/00A patent/AU777234B2/en not_active Ceased
- 2000-02-10 PL PL350413A patent/PL201844B1/en unknown
- 2000-02-10 AT AT00906318T patent/ATE258046T1/en active
- 2000-02-10 ES ES00906318T patent/ES2215025T3/en not_active Expired - Lifetime
- 2000-02-10 HU HU0200336A patent/HUP0200336A3/en unknown
- 2000-02-10 JP JP2000598142A patent/JP2002536401A/en active Pending
- 2000-02-10 BR BRPI0008442-5A patent/BR0008442B1/en not_active IP Right Cessation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103610656A (en) * | 2013-12-05 | 2014-03-05 | 昆明振华制药厂有限公司 | Preparation method of analgin tablet |
| US20160317662A1 (en) * | 2013-12-16 | 2016-11-03 | Hypermarcas S.A. | Stable oral pharmaceutical composition |
| CN104434862A (en) * | 2014-11-06 | 2015-03-25 | 石家庄正大鸿福牧业有限公司 | Veterinary metamizole sodium effervescent tablets and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0200336A3 (en) | 2005-04-28 |
| BR0008442A (en) | 2001-10-09 |
| TR200102279T2 (en) | 2001-11-21 |
| ATE258046T1 (en) | 2004-02-15 |
| ES2215025T3 (en) | 2004-10-01 |
| EP1150660B1 (en) | 2004-01-21 |
| EP1150660A1 (en) | 2001-11-07 |
| HUP0200336A2 (en) | 2002-06-29 |
| DE50005076D1 (en) | 2004-02-26 |
| JP2002536401A (en) | 2002-10-29 |
| AU777234B2 (en) | 2004-10-07 |
| CA2362757C (en) | 2010-08-24 |
| BR0008442B1 (en) | 2014-04-01 |
| PT1150660E (en) | 2004-06-30 |
| PL350413A1 (en) | 2002-12-02 |
| PL201844B1 (en) | 2009-05-29 |
| WO2000047189A1 (en) | 2000-08-17 |
| AU2804000A (en) | 2000-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5629013A (en) | Chewable calcium carbonate antacid tablet compositions | |
| US5312626A (en) | Lozenge or chewable tablet | |
| US5244670A (en) | Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress | |
| CA1329130C (en) | Ranitidine | |
| US3970750A (en) | Effervescent potassium chloride composition | |
| US6242002B1 (en) | Effervescent formulations | |
| US5869095A (en) | Chewable tablet with an effervescent action | |
| US5401514A (en) | Solid, fast-soluble pharmaceutical preparation containing S-(carboxymethyl)-L-cysteine and/or N-acetylcysteine | |
| US20050215643A1 (en) | Pharmaceutical compositions based on diclofenac | |
| JPH11514629A (en) | Stable thyroid hormone containing drugs | |
| CA2254144C (en) | Pharmaceutical compositions based on diclofenac | |
| US20040022866A1 (en) | Pharmaceutical compositions with antibiotic activity | |
| KR100187951B1 (en) | Composition for foaming preparation | |
| US5728401A (en) | Effervescent ranitidine formulations | |
| US9427421B2 (en) | Effervescent compositions containing N-acetylcysteine | |
| CA2362757A1 (en) | Effervescent pharmaceutical formulation containing metamizole | |
| US5720977A (en) | Oral water soluble pharmaceutical compositions containing estrone compound and calcium salt | |
| EP0346866A2 (en) | Composition for the prophylaxis of osteoporosis | |
| WO2005123041A1 (en) | Oral dispersible tablet composition of amoxycillin and/or clavulanic acid comprising a surface-modified sodium bicarbonate | |
| UA79567C2 (en) | Orodispersible pharmaceutical composition of antithrombolic compound | |
| RU2276982C2 (en) | Agent possessing with anti-inflammatory, analgesic and antipyretic effect as tablet | |
| ES2279707B1 (en) | ORAL FORMULATIONS THAT INCLUDE 3'-AZIDONUCLEOSIDS. | |
| GB2285923A (en) | Pharmaceutical powder containing N-acetyl-cysteine | |
| MXPA01008150A (en) | Pharmaceutical effervescent formulation containing metamizol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20140211 |